Gilde Healthcare company Big Health expands into adolescent mental health through acquisition of Limbix - Gilde Healthcare

Gilde Healthcare company Big Health expands into adolescent mental health through acquisition of Limbix

July 17, 2023
London (UK) & Utrecht (the Netherlands)

Big Health, the leading provider of non-drug digital treatments for mental health, has acquired Limbix, creators of the first, evidence-based digital therapeutic for teens and young adults with symptoms of depression. Since its founding in 2016, Limbix has raised $30 million and has built a research-based pipeline of adolescent products. As a result of the transaction, Big Health’s therapeutic portfolio expands to include SparkRx for adolescent depression and an adolescent anxiety product in development, alongside its flagship programs for patients aged 18+: Sleepio, for insomnia, and Daylight, for anxiety.

SparkRx is designed to overcome common barriers to mental health care access, meeting young people on their smartphones, and is supported by trial data demonstrating a clinically meaningful reduction in depression symptoms. The self-guided, cognitive behavioral therapy (CBT) based treatment for those aged 13+ teaches skills such as mood tracking, behavioral activation, problem solving and mindfulness.

The addition of SparkRx also enables the company to deliver on a critical customer need, as employers and health plans increasingly seek ways to provide effective treatments across a broader age range. In addition to health care providers, SparkRx will be made available to Big Health’s employer, public sector, health systems and health plan customers, and through the company’s strategic distribution agreements with pharmacy benefit managers (PBMs), significantly increasing nationwide access. To date, more than 300,000 patients have enrolled in treatment through one of Big Health’s digital therapeutics.

About Big Health
Big Health’s mission is to help millions back to good mental health by providing safe and effective non-drug treatments for the most common mental health conditions, including insomnia, anxiety and depression. Designed by leading clinical experts, Big Health’s digital therapeutics expand access to gold standard care, including behavioral medicine, and are backed by over 80 industry-leading research and 15 randomized controlled trials. By seamlessly integrating across the care pathway, from member engagement to billing via pharmacy benefit managers, Big Health simplifies adoption for employers, payers and patients, providing an inclusive, scalable, and affordable approach without serious side effects. For more information, please visit or follow Big Health on LinkedIn and Twitter.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €2.5 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
May 21, 2024

Gilde Healthcare co-leads $100M equity financing in Karius

Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Gilde Healthcare, Khosla Ventures and 5AM Ventures, and...
May 2, 2024

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of...
April 11, 2024